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Abstract: Exemestane is a third-generation aromatase inhibitor, which has proven to be a useful 
drug in the treatment of early stage breast cancer. Several clinical trials have been performed 
or are currently underway using exemestane as adjuvant therapy in postmenopausal women, 
which will be the indication reviewed here. A relative reduction in risk of breast cancer recur-
rence or death of 24% has been shown with exemestane compared with tamoxifen when given 
after 2 to 3 years of tamoxifen. This corresponded to a 3.3% absolute reduction in recurrence or 
death at the end of 5 years, for a number needed to treat of 30. The main use of exemestane in 
the adjuvant setting is as an alternative to tamoxifen, and toxicities are discussed in relation to 
tamoxifen toxicities. In general, patients receiving exemestane experience less hot ﬂ  ashes and 
more arthralgias in comparison to tamoxifen, while there is also a reduction in venous thrombo-
embolic events and vaginal bleeding. Patients on exemestane as a group do not appear to have 
a signiﬁ  cantly changed quality of life in comparison to tamoxifen, while having a statistically 
signiﬁ  cant beneﬁ  t in preventing breast cancer recurrence.
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Background
Exemestane (6-methylenandrosta-1,4-diene-3,17-dione) is a third-generation 
irreversible aromatase inhibitor currently in clinical use for the treatment of both 
advanced and early breast cancer. This review will focus on its role in the adjuvant 
treatment of breast cancer.
Breast cancer is the most prevalent cancer in women worldwide, and responsible 
for the greatest number of deaths.1 Almost half a million women will die of breast 
cancer each year. In the developed countries, approximately 70% of breast cancers 
express the estrogen receptor,2 and hormonal manipulation in terms of blocking or 
inactivating the receptor, or reducing the amount of estrogen available, has been an 
important advance in the treatment of these women.3 In the late 1800s, case reports of 
oophorectomy beneﬁ  ting patients with breast cancer4 and the subsequent application 
in the 1950s of oophorectomy and adrenalectomy for patients with advanced breast 
cancer, set the foundation for the critical role that hormonal manipulation currently 
plays in the treatment of breast cancer.5
In the setting of adjuvant treatment of early breast cancer, anti-estrogen therapy 
has been shown to reduce the risk of breast cancer recurrence and death. The standard 
for the adjuvant hormonal treatment for early stage breast cancer has been tamoxifen 
citrate (tamoxifen), a selective estrogen receptor modulator (SERM).3 As a SERM, 
tamoxifen exerts both antagonistic and agonistic effects on the estrogen receptor, 
depending on the tissue, the hormonal milieu, and possibly depending on what other 
receptor pathways and coregulators are activated. Tamoxifen has been well studied in 
over 20,000 women, and reduces the risk of death by a relative amount of 22%, and 
the risk of recurrence by 42%.3Therapeutics and Clinical Risk Management 2009:5 92
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Despite the clinical success of tamoxifen, attempts have 
been made to ﬁ  nd alternate pharmacologic strategies with a 
greater therapeutic index in the adjuvant setting. Exemestane 
has been shown to modestly improve efﬁ  cacy in terms of 
breast cancer recurrence, and to modestly reduce adverse 
events such as endometrial cancer, and venous thromboem-
bolism.6 This review will focus on the pharmacologic and 
clinical aspects of exemestane as adjuvant treatment in early 
breast cancer.
Pharmacologic properties
Exemestane is an irreversible, highly speciﬁ  c, inhibitor of the 
cytochrome p450 enzyme, aromatase. Aromatase is an enzyme 
found in many tissues, including adipose, skin, adrenal, and 
breast tissue (and in breast tumor tissue) and is a catalyst for 
the ﬁ  nal step of estrogen synthesis, the NADPH-dependent 
conversion of androstenedione to estrogens.7 The aromatase 
enzyme is located intracellularly, in the endoplasmic reticulum. 
Because current aromatase inhibitors target this ﬁ  nal step of 
estrogen synthesis, little effect on other adrenal hormones 
occurs. Exemestane is a molecule with a steroidal structure 
similar to androstenedione, and it acts as a false substrate for 
aromatase. Once it is recognized by aromatase, it is converted 
to an intermediate which binds irreversibly to the aromatase 
enzyme, thus inactivating it. For estrogen synthesis to begin 
again, new aromatase must be produced.
Exemestane is highly bioavailable, with 42% oral avail-
ability. The plasma half-life of exemestane is 27 h, and 
the time to steady state concentration is 7 days or less.8 
Exemestane is metabolized by the CYP3A4 system, although 
clinically signiﬁ  cant interactions with CYP3A4 inhibitors 
such as ketoconazole have not been demonstrated.9 CYP3A4 
inducers, such as phenytoin, may lower plasma concentra-
tions of exemestane, although again the clinical signiﬁ  cance 
is unclear. Excretion occurs via both the hepatic and renal 
pathways, however dose adjustments are not necessary.
Pharmacodynamically, exemestane exerts its effects 
by irreversibly inactivating the aromatase enzyme. Plasma 
estrogen levels drop by 90% in postmenopausal women, with 
systemic drops in estrone of 95% and estradiol of 85%, as 
well as estriol, after a single dose of 25 mg. Estrogen levels 
remain suppressed for 4 days, despite the half-life of exemes-
tane being considerably shorter.8 This is due to the fact that 
exemestane irreversibly inhibits the aromatase enzyme. 
Exemestane also inhibits intratumoral levels of estrogen, 
although the clinical signiﬁ  cance of this is not clear.10
Although not currently standard of care in premenopausal 
patients, it is important to note that when exemestane is given 
in combination therapy with the LHRH agonist triptorelin 
in premenopausal patients, a signiﬁ  cant drop of estrogen 
levels in premenopausal patients results, in comparison to 
triptorelin alone.11
Clinical effectiveness in early breast 
cancer
Exemestane has been studied in the adjuvant setting in post-
menopausal patients in a series of trials that are either completed 
or ongoing. In the postmenopausal adjuvant setting, the land-
mark International Exemestane Study (IES) investigated the use 
of exemestane for 2 to 3 years following the use of tamoxifen 
for 2 to 3 years.12 The Tamoxifen or Exemestane Adjuvant 
Multicentre study (TEAM) initially was designed to investigate 
5 years of tamoxifen versus 5 years of exemestane, but after 
the results of the IES study were known it was amended to 
investigate the option of 5 years of exemestane versus 5 years 
of a tamoxifen followed by exemestane sequence (ie, similar to 
the experimental arm of the IES study).13 The National Cancer 
Institute of Canada (NCIC) is currently running the MA-27 
study, which is a direct comparison of the steroidal aromatase 
inhibitor exemestane with the non-steroidal aromatase inhibitor 
anastrozole. This will be the ﬁ  rst study to look at whether there 
are any signiﬁ  cant differences between the third generation 
aromatase inhibitors. The NSABP B-33 study examined the 
question of whether exemestane was beneﬁ  cial after 5 years 
of tamoxifen treatment, and was the only trial with a placebo 
control.14 This study was stopped early due to the results of other 
aromatase inhibitors showing beneﬁ  t in a similar setting.
In the premenopausal setting, exemestane is being 
investigated in combination with ovarian suppression in the 
Suppression of Ovarian Function Trial (SOFT study), which 
is randomizing patients to tamoxifen alone, or to ovarian 
suppression with tamoxifen, or to ovarian suppression with 
exemestane. The Tamoxifen or Exemestane Trial (TEXT) is 
comparing tamoxifen with exemestane in patients with ovar-
ian suppression with a LHRH agonist – triptorelin.15
In the neoadjuvant setting, exemestane has been studied 
in both randomized controlled trials and in many phase 2 
settings. While these trials have raised some interesting 
biological questions, and neoadjuvant exemestane may be 
an option in locally advanced elderly patients,16–18 the clini-
cal relevance of neoadjuvant aromatase inhibition in early 
breast cancer is minimal.
The IES study
The IES study, which was a landmark study, randomized 
patients who had received 2 to 3 years of tamoxifen for adjuvant Therapeutics and Clinical Risk Management 2009:5 93
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breast cancer treatment to either continue tamoxifen or switch 
to exemestane for the duration of 5 years. 4724 patients were 
enrolled on the study, all of whom were postmenopausal. As 
of the most recent published analysis, median follow-up was 
55.7 months. Disease-free survival, deﬁ  ned in this study as 
a composite endpoint of death from any cause, new breast 
cancer, or recurrence of breast cancer at any site, was statisti-
cally signiﬁ  cantly improved, with a relative improvement of 
24% (hazard ratio [HR] 0.76). Overall survival approached 
statistical signiﬁ  cance, and when the subset of patients with 
known estrogen receptor negativity was excluded, risk of death 
was 17% lower in the exemestane group, with an HR ratio of 
0.83, and 95% conﬁ  dence intervals (CI) just touching unity 
(0.69–1.00).12
The patients in the IES study represented patients who 
had already received at least 2 years of tamoxifen without 
recurrence, and had very strict deﬁ  nitions of postmeno-
pausal status. Patients had to have no menses for 2 years 
and be over age 55, or have had no menses from 1 year 
before cancer diagnosis. In other words, patients in their 
40s who became amennorheic with chemotherapy would 
not have been eligible for this study. Approximately half of 
the patients were node negative, half had primary tumors 
less than 2.0 cm (ie, T1), and two thirds were greater than 
60 years old. The absolute beneﬁ  t in the trial population 
group in comparison to tamoxifen was 3.3%, meaning that 
in a similar selection of patients, roughly 30 patients would 
need to be treated with exemestane to prevent one recur-
rence or death at the end of 5 years. The absolute differ-
ence in death at the end of treatment was 0.72% in patients 
without estrogen receptor positivity, for a number needed 
to treat of roughly 138 patients to prevent 1 death.
The NSABP B-33 study
The NSABP B-33 study enrolled patients who had com-
pleted 5 years of tamoxifen. Patients were randomized to 
placebo or exemestane for a further 5 years, with a planned 
sample size of 3000 patients. The trial was terminated 
early due to the results of the NCIC MA-17 study which 
enrolled a similar group of patients to a trial comparing 
placebo and the non-steroidal aromatase inhibitor letrozole. 
In that study, letrozole was associated with a statistically 
signiﬁ  cant improvement of disease-free survival, with a 
4.6% absolute improvement in disease-free survival at 
4 years (p  0.001), and a subset analysis of overall sur-
vival showed beneﬁ  t in node-positive patients. Thus, it was 
elected to terminate NSABP-B33 early, with an accrual of 
1598 patients.
The results of this study were not statistically positive, 
possibly due to the attenuated accrual and thus lack of statisti-
cal power. The HR for overall survival was 1.20, with CI from 
0.57 to 2.52. This study will be important to add to future 
meta-analyses of the utility of extended adjuvant therapy. 
In terms of disease-free survival, a 2% absolute reduction 
in disease free survival was seen for the exemestane arm, 
although this again did not meet statistical signiﬁ  cance due 
to the lack of power (p = 0.07). A third endpoint of the trial, 
recurrence-free survival, did show a statistically signiﬁ  cant 
advantage of exemestane over placebo, with 94% of patients 
being breast cancer relapse free at 4 years, with 96% in the 
exemestane arm being breast cancer relapse free. The major-
ity of this beneﬁ  t was due to reduced local recurrence and 
contralateral breast cancer. The number of deaths in trial 
was very few, with only 13 deaths in the placebo arm and 
16 deaths in the exemestane arm. Whether exemestane is a 
reasonable option for patients who cannot tolerate or obtain 
letrozole in the extended adjuvant setting is controversial, 
and depends on how one weighs the beneﬁ  ts of breast cancer 
recurrence prevention with the lack of beneﬁ  t thus far in 
terms of overall survival.14
In terms of trials using 5 years of exemestane as the 
initial adjuvant treatment, there are as yet no completed and 
reported clinical trials using this strategy. The MA27 study, 
compares exemestane with anastrozole for 5 years, and the 
TEAM study compares the ‘sequence strategy’ of tamoxifen 
and exemestane with 5 years of exemestane straight. Both 
of these trials will be looking at 5 years of exemestane as 
the experimental treatment, with different comparison arms. 
Currently, 5 years of upfront exemestane treatment should 
not be considered an appropriate therapy based on the com-
pleted clinical trials.
Pre- and peri-menopausal patients
In the pre-menopausal setting, the majority of estrogen 
production occurs in the ovaries, and inhibition of adrenal 
and peripheral aromatase as a sole-modality of treatment 
is does not lower systemic estrogen levels to a signiﬁ  cant 
amount. Thus, in the pre-menopausal setting, exemestane 
in addition to ovarian suppression is being evaluated as an 
adjuvant strategy. The SOFT study – the Suppression of 
Ovarian Function study – is a three armed study of various 
anti-estrogen strategies in pre-menopausal patients, includ-
ing tamoxifen alone, ovarian suppression plus tamoxifen, 
or ovarian suppression plus exemestane. The TEXT study 
is simply randomizing patients between ovarian suppression 
plus tamoxifen versus ovarian suppression plus exemestane. Therapeutics and Clinical Risk Management 2009:5 94
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Results from these two trials are anticipated, but currently 
exemestane is not an evidence based option for the adjuvant 
treatment of premenopausal breast cancer.
In addition, premenopausal patients who become amen-
norheic after chemotherapy and are treated with exemes-
tane, may have ovarian function return. An audit from the 
Royal Marsden Hospital of patients over the age of 40 who 
had chemotherapy induced amenorrhea and subsequently 
received an aromatase inhibitor showed that 27% of 
patients recovered ovarian function, which was higher than 
anticipated. A signiﬁ  cant proportion of these had received 
tamoxifen for 1 to 3 years prior to switching to an aromatase 
inhibitor. Aromatase inhibitors such as exemestane should 
only be used with extreme caution in patients under 50 with 
chemotherapy induced amenorrhea, if at all.19
Toxicities
In assessing the toxicities associated with exemestane, it is 
important to compare the toxicities with those of tamoxifen, 
given that the major use of exemestane is in a substitution 
for tamoxifen at the 2- to 3-year mark. The NSABP-B33 
trial comparing exemestane to placebo gives some idea as 
to what toxicities are truly due to exemestane, as will the 
current exemestane prevention study (ExCel) in patients 





Exemestane has a clear advantage over tamoxifen in the risk 
of venous thromboembolic disease. Tamoxifen, a partial 
estrogen agonist, does increase the risk of thromboembolism 
slightly over baseline.20 In the IES study, venous throm-
boembolic disease, deﬁ  ned as deep venous thrombosis or 
pulmonary embolism, occurred in 2.3% of patients in the 
tamoxifen arm and 1.2% of patients in the exemestane arm. 
This difference was statistically signiﬁ  cant (p = 0.004). No 
patients in either arm had documented death due to venous 
thromboembolic disease.12
In terms of cardiovascular events, 16.5% of patients 
in the exemestane arm and 15.0 percent of patients in the 
tamoxifen arm had a cardiovascular event. This includes 
8.0% of people and 6.9% of people having ischemic heart 
event respectively. These differences did not reach statistical 
signiﬁ  cance (p = 0.16 and p = 0.17 respectively).12 It can be 
concluded from this study, that at least as far as 5 years from 
switching to exemestane, there was no statistically signiﬁ  cant 
detriment in terms of cardiovascular events by using the 
steroidal aromatase inactivator exemestane.
It should be noted that if a 1.1% absolute increase in 
thromboembolic events is considered within the realm of 
clinical signiﬁ  cance, then an absolute increase of 1.1% 
increase in ischemic heart events would also be expected to 
be within the realm of clinical signiﬁ  cance. However, given 
the rare nature of venous thromboembolic events in compari-
son to ischemic heart events in the population, the chance 
of determining a statistically signiﬁ  cant difference with the 
same absolute difference is much higher for rare events.
Bone fractures
Just as thromboembolic and cardiovascular events range from 
relatively easily treated events with a low likelihood of mortal-
ity to more serious events such as life threatening pulmonary 
embolism, so too do bone fractures range in severity from 
fractures associated with some morbidity, such as Colles’ 
fractures and vertebral fractures, to fractures associated with a 
high mortality, such as hip fractures in the elderly.21 Tamoxi-
fen may exert some bone protective effects, as measured 
by an increase in bone-density. In clinical trials compared 
with placebo, tamoxifen was shown to possibly reduce the 
incidence of osteoporotic fractures by 19%, although this 
did not reach statistical signiﬁ  cance.22 A recent population 
based study also showed that tamoxifen use was associated 
with a reduced rate of fractures.23 There is controversy over 
how bone protective tamoxifen is, however, and how long 
the effect lasts, as increases in bone density do not always 
equate with fracture prevention.24 Given the similar beneﬁ  t for 
osteoporotic fractures seen with the selective estrogen receptor 
modulator raloxifene, as well as various observational studies 
with tamoxifen, it is likely that there is probably a decrease in 
fracture risk with tamoxifen.
Aromatase inhibition with exemestane, which further 
lowers postmenopausal estrogen levels, has the concern of 
further exacerbating the natural bone-loss of menopause. 
Information from the IES and TEAM studies will not tell 
us whether exemestane has a detrimental effect on bone 
structure or bone density scores, but will tell us if the effect 
is different from tamoxifen. Data from the NSABP-B33 
study, and the exemestane prevention studies, will tell us 
what the risk of bone problems is in relation to placebo, and 
data from the MA27 study will tell us how the risk of bone 
metabolism issues with a steroidal aromatase inactivator such 
as exemestane compares with the non-steroidal aromatase 
inhibitor exemestane.Therapeutics and Clinical Risk Management 2009:5 95
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In the IES study, at a median follow-up in of 58 months, 
162 (7%) and 115 (5%) patients in the exemestane and 
tamoxifen groups, respectively, had fractures (odds ratio 1.45 
[1.13–1.87]; p = 0.003). In other words, 50 patients would need 
to be treated with exemestane instead of tamoxifen in order to 
see one additional fracture (number needed to harm = 50). This 
number must be compared to the number needed to treat of 
33 to prevent one death or breast cancer recurrence. In terms 
of bone density as measured by DEXA scans, and markers of 
bone turnover such as n-telopeptides, there was statistically 
signiﬁ  cant loss of bone density and increase in biochemical 
markers in the ﬁ  rst year of switching. The amount of bone 
density loss decreased from the ﬁ  rst to second year.25
In the NSABP B-33 study, very few fractures had 
occurred, with 28 fractures in the exemestane group and 20 in 
the placebo group (3.5% vs 2.6% p = NS). Further data on 
incidences of osteopenia, or other bone-related abnormali-
ties, are awaited. As this study was unblinded earlier than 
anticipated, and 44% of patients who had been randomized to 
placebo subsequently crossed over to receive exemestane, the 
fracture rates will not be indicative of 5 years of exemestane 
compared to 5 years of placebo.14
Bone mineral density abnormalities and fractures are a 
recognized complication of aromatase inhibitor therapy, and 
may occur after treatment has been discontinued. Appropri-
ate attention to bone density monitoring, and the initiation 
of bone health strategies are advised. In addition to anti-
resorptive pharmacologic therapies such as bisphosphonates, 
other aspects of osteoporosis fracture prevention, such as 
fall prevention, avoidance of CNS depressant drugs such as 
benzodiazepines in persons at risk of fracture, encouragement 
of weight bearing exercise, and other general bone health 
strategies are advised.26
Lipid side-effects
Although cardiovascular events in the ﬁ  rst 5 years were not 
statistically signiﬁ  cantly adversely effected by exemestane in 
relation to tamoxifen, there may be an effect on lipid proﬁ  les. 
In the TEAM study comparing exemestane with tamoxifen, 
a substudy was done looking at the effects on lipid proﬁ  les 
of the two drugs. 176 patients were included in this study, 
with lipid proﬁ  les including HDL, LDL, triglycerides, and 
total cholesterol, measured at different time points. There 
was a decrease in total cholesterol in the tamoxifen group 
by 9.9%, and a decrease in the exemestane group of 1.9% 
(p = 0.039) at 12 months. Triglyceride levels were higher 
in the tamoxifen arm, while LDL levels were higher in the 
exemestane arm at the 3- and 6-month mark.27 It is unclear 
whether such minor differences in lipid proﬁ  les will result in 
any signiﬁ  cant clinical outcomes at later time periods.
Gynecologic side-effects
The association of tamoxifen with endometrial cancer has 
been well established. In terms of absolute numbers, tamoxi-
fen therapy increases the risk of endometrial cancer by 1 case 
per 1000 women treated with tamoxifen per year.28 Although 
many of these cancers are caught early, the risk of death from 
endometrial cancer does exist. In the IES study, there was 
no signiﬁ  cant difference in endometrial cancers between the 
exemestane and tamoxifen arms, and risks were very low. The 
tamoxifen treated patients did have a higher rate of vaginal 
bleeding, a higher rate of vaginal discharge, and a higher rate of 
dilatation and curettage.12 In the IES Quality of Life substudy, 
there was less vaginal discharge associated with exemestane, 
with no signiﬁ  cant increase in vaginal dryness.29 In contrast, 
in the TEAM study, exemestane patients, in contrast, had 
signiﬁ  cantly higher rates of vaginal dryness in comparison to 
tamoxifen treated patients.30 In addition, atrophic vaginitis has 
been reported to be as common as 20% in patients receiving 
aromatase inhibitors.31 The management of vaginal dryness in 
patients on aromatase inhibitors generally begins with topical 
non-hormonal lubricants. Hormonal based vaginal supposi-
tories and creams, may increase systemic estrogen levels in 
these patients, which is an effect not generally wanted in breast 
cancer.32 It is unclear at this time whether lower dose topical 
estrogens, such as Estring®, are entirely safe, or whether it is 
better to switch these patients back to tamoxifen. Aromatase 
inhibitors, including exemestane, lead to an increase in reported 
dyspareunia, and may lead to decreased sexual satisfaction.33
Non-gynecological menopausal-type 
side-effects
Estrogen deprivation with aromatase inhibitors has other 
side-effects apart from the gynecological tract and bone 
metabolism. Hot ﬂ  ashes are generally less with exemestane 
than with tamoxifen, and tend to peak at around three months. 
In contrast, the incidence of decreased libido is slightly 
greater with exemestane (possibly in part due to the dyspa-
reunia secondary to vaginal dryness), and difﬁ  culty sleeping 
occurs more frequently with exemestane in comparison to 
tamoxifen. Effects on cognitive abilities do not appear to be 
signiﬁ  cantly different.30
Arthralgias and myalgias
One of the most frequent side-effects experienced by 
patients on aromatase inhibitors, including exemestane, is Therapeutics and Clinical Risk Management 2009:5 96
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that of muscle and joint aches. In the IES study, arthralgia, 
carpal tunnel syndrome, joint stiffness, and paresthesia were 
reported in more patients in the exemestane arm than in 
the tamoxifen arm. In terms of arthralgia, 18.6% of patients 
on the exemestane arm reported arthralgia, compared with 
11.8% in the tamoxifen arm. Musculoskeletal pain also 
occurred more frequently on the exemestane arm, with 21.0% 
of patients in the exemestane arm and 16.1% of patients in 
the tamoxifen arm experiencing this pain.12 Whether these 
relatively low numbers are representative of clinical practice 
in the “real world” setting has been a matter of debate, as 
reported incidences of musculoskeletal complaints in many 
series signiﬁ  cantly exceeds 21%. A recent survey of patients 
taking aromatase inhibitors for early stage breast cancer 
showed that the reported incidence of joint pain or stiffness 
was greater than 40%.34 Evidence from more recent studies, 
such as the MA27 study, may give a better idea of the inci-
dence, given the increased awareness of this phenomenom 
with clinical experience. The issue of the true incidence of 
aromatase inhibitor joint toxicity is difﬁ  cult to evaluate from 
clinical trials, given the inadequacy of the commonly used 
observer related grading systems used to assess these long 
term subjective issues.
The mechanism of the joint and muscle complaints is 
not fully understood currently. Certainly, the incidence of 
carpal tunnel syndrome in the IES study of 2.8%, compared 
with the incidence of 0.3% in the tamoxifen arm, suggests 
a certain biological phenomenom. In addition, MRI studies 
have shown increased tenosynovial thickening in patients 
on aromatase inhibitors, and objective measurement of joint 
function, such as grip strength is impaired in patients on 
aromatase inhibitors.35
Management of exemestane associated arthralgias and 
myalgias includes conventional maneuvers such as exercise 
and analgesia.36 If symptoms persist, one can decide based on 
the baseline risk of death from cancer in the patient whether 
continuing with exemestane and adding anti-inﬂ  ammatory 
medicines or acetaminophen is warranted, or whether switch-
ing to different aromatase inhibitors and possibly back to 
tamoxifen would be reasonable. Certainly, the balance 
between the risks of a small increase in breast cancer recur-
rence in comparison with the risks of polypharmacy, long 
term issues with anti-inﬂ  ammatory medicines, for example, 
must be weighed on an individual level.37 In addition, it is 
unclear whether the symptoms of arthralgias are indicative 
of true joint damage, and whether this symptom should be 
masked. Estrogen replacement therapy, in some studies, 
has been shown to lower the incidence of osteoarthritis in 
postmenopausal women,38 and it is plausible that further 
lowering of estrogen beyond that of a postmenopausal woman 
will exacerbate osteoarthritis. While controlling symptoms 
with analgesia may increase the compliance associated with 
aromatase inhibitors such as exemestane, it is unclear if the 
underlying joint damage is still occurring in the absence 
of symptoms. Again, the known beneﬁ  ts in terms of breast 
cancer reduction must be weighed in the individual patient 
against the known current toxicities, and possible future 
toxicities such as need for joint replacement.
Side-effects and compliance
In the IES quality of life substudy, 582 patients were enrolled 
and completed validated questionnaires evaluating quality of 
life. At the 6-month mark, the composite QOL indicator – the 
trial outcome index (TOI) was statistically signiﬁ  cantly 
lower among patients receiving exemestane.29 However, by 
the 12-month mark the TOIs return to similar levels. This 
difference, although statistically signiﬁ  cant, is below the 
level accepted as clinically signiﬁ  cant. Importantly from this 
study, it would appear that quality of life may worsen and 
then improve on exemestane.
In the IES trial, 2352 patients were randomized to 
exemestane, and 513 of these patients did not ﬁ  nish treatment. 
While 133 patients discontinued treatment due to death or 
disease recurrence, a further 321, or 14%, discontinued due 
to adverse events or patient refusal.12 Both a chart review 
of patients receiving adjuvant aromatase inhibitor therapy 
in Ottawa, Canada, and a large database analysis from the 
United States, have shown discontinuation or non-adherence 
rates in the 20% range. Reasons for discontinuing drug vary, 
and are comparable to discontinuation rates with tamoxifen. 
Reasons for discontinuation may be complex, and include 
physical reasons such as arthralgias, myalgias, hot ﬂ  ashes, 
vaginal dryness, sleep disturbances. Management of these 
side-effects, reassurance of the transient nature of some of 
these effects, and acknowledgement of these side-effects 
are all strategies to reduce the discontinuation of this drug.36 
Because other aromatase inhibitors, and other anti-estrogen 
strategies such as tamoxifen also have proven efﬁ  cacy in 
breast cancer, changing treatments is an option in the face 
of intolerable, or difﬁ  cult to manage side-effects.
A recent study by Thomas et al examined switching to 
letrozole or exemestane in patients who had signiﬁ  cant hot 
ﬂ  ashes with tamoxifen.39 This study included 80 women with 
greater than NCI grade 3 hot ﬂ  ashes, or had an average of 14 
hot ﬂ  ashes per week, who switched to exemestane. At 3 months 
after switching, 68% of the patients preferred exemestane over Therapeutics and Clinical Risk Management 2009:5 97
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tamoxifen, while 38% of patients preferred tamoxifen. A minor-
ity of patients, 10%, switched back to tamoxifen due to intoler-
able side-effects. This study conﬁ  rms the beneﬁ  cial effects of 
exemestane on hot ﬂ  ash symptomology, and the detrimental 
effects of arthralgias. It also conﬁ  rms that for patients intolerant 
of tamoxifen, switching to exemestane may be beneﬁ  cial for 
their quality of life for some patients. Importantly, almost all 
patients (99%) appreciated the opportunity to experience both 
drugs, and thus to decide for themselves which drug ﬁ  ts best 
into their life-style.
Summary
Exemestane has a proven beneﬁ  t in the treatment of early 
stage breast cancer, and currently is used in postmenopausal 
patients, usually as a “switch” strategy after tamoxifen. The 
use of exemestane is undergoing active clinical trials in other 
scenarios, such as in premenopausal patients in conjunction 
with ovarian ablation, or in postmenopausal patients who 
have not received 2 years of tamoxifen, and in the prevention 
of breast cancer in high risk women.
While patients need to be counseled regarding the 
improved breast cancer outcomes and overall survival 
outcomes related to the usage of exemestane, they also need 
to be aware of the potential reduction in tamoxifen related 
toxicities, and in the potential increase in aromatase inhibitor 
related toxicities. Management of the side-effects and toxici-
ties associated with exemestane involves attention to the bone 
health, joint health, as well as the vaginal and sexual health 
of postmenopausal patients with breast cancer.
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